The findings revealed that patients with glioma with high expression of adducin 2 (ADD2), CST telomere replication complex component 1 (CTC1), SRC kinase signaling inhibitor 1 (SRCIN1), RAR related orphan receptor A (RORA), vacuolar protein sorting four homolog A (VPS4A), and unc-51 like autophagy activating kinase 2 (ULK2) had a longer survival than those with low expression (Figures 5C–H). This evidence concerns the gene ULK2 and central nervous system cancer.